Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T Rowe Price Group Inc (TROW) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance

T Rowe Price Group IncTrade
Health Care Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

T Rowe Price Group Inc vs Health Care Select Sector SPDR Fund — how do they compare? T Rowe Price Group Inc trades at $111.71 (market cap $24.26B), while Health Care Select Sector SPDR Fund trades at $166.97. The key difference: T Rowe Price Group Inc pays a 4.57% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, T Rowe Price Group Inc nearer its low. Which is the better fit depends on your goals.

TROWXLV
Market Cap
$24.26B
Sector
Financials
52-Week High
$121.68$168.44
52-Week Low
$86.19$131.16
Enterprise Value
$21.46B
Dividend Yield
4.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T Rowe Price Group Inc

T. Rowe Price Group (TROW) trades at $113.77, down 0.22% on the day, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a 29.26% net income margin and a P/E of 11.42, indicating potential undervaluation. Recent Q2 2026 earnings beat expectations at $2.57 per share, supported by record assets under management and higher advisory fees, though expenses and net outflows remain headwinds.

The outlook is cautiously optimistic with earnings growth and dividend stability offering upside, but risks include expense pressures and market volatility. Analyst consensus is a Hold with a $112.17 price target, near the current price, suggesting limited near-term momentum. Institutional activity shows mixed positioning, reflecting balanced risk-reward.

Health Care Select Sector SPDR Fund

XLV, the Health Care Select Sector SPDR ETF, trades at $167.1, down 0.8% on the day. The technical outlook is bullish based on moving averages, though short-term oscillators signal overbought conditions. Recent news highlights the ETF's defensive appeal amid economic uncertainty and its competitive edge with a low 0.08% expense ratio. Strong healthcare earnings and investor inflows into defensive sectors support positive momentum.

The outlook for XLV is positive, driven by defensive sector demand and solid underlying holdings. Key opportunities include cost efficiency and diversification across 60 healthcare stocks. Risks involve sector-specific pressures like regulatory changes and liquidity challenges. Analyst sentiment remains favorable, with the ETF well-positioned for steady growth in a volatile market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About T Rowe Price Group Inc

T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.

Read more on TROW

About Health Care Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Read more on XLV